Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we
Welcome to the Rare Classroom, a new series from Patient Worthy. Rare Classroom is designed for the curious reader who wants to get informed on
Want to learn about scientific topics without needing a PhD? Check out the Science Simplified blog from TESS Research Foundation! Dr. Tanya Brown, PhD, works
On November 15, 2022, the Rare Disease Legislative Advocates (RDLA) hosted their monthly webinar. These webinar help provide updates to the rare disease community on
Did you know that November is considered to be Hyperhidrosis Awareness Month? This awareness campaign is intended to share information about hyperhidrosis (a medical condition
Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we
I can’t believe I suffered needlessly for 26 years with eosinophilic esophagitis (EoE) and life-threatening food impaction episodes. I saw three GI doctors and underwent
According to a story from PR Newswire, Immunic, Inc., a biopharmaceutical company prioritizing the development of oral immunology medicines for the treatment of chronic inflammatory
The loss of axons (nervous system wiring) has been responsible for various neurodegenerative diseases such as peripheral neuropathies, Parkinson’s disease, glaucoma, and amyotrophic lateral
Mahesh Karande, the President and CEO of Omega Therapeutics, is incredibly passionate about epigenetics. And it shows: in the work that he and his team
In the ongoing search for prevention and a cure for Alzheimer’s Disease (AD), a study was conducted at Colorado’s Anschutz Medical Campus. The researchers found
Real World Evidence Note: This story was originally published by our partner organization TREND Community. You can check out the original publication here. When I
If you ask college basketball fans in Tennessee, they’ve probably heard of Zakai Zeigler. The 5’9 point guard, who originally hails from Long Island, now
So far, the Phase 2 EMPOWER-CSCC-1 clinical study has evaluated cemiplimab (also known as Libtayo) in individuals with locally advanced or metastatic cutaneous squamous
© Copyright Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
